Informed use of bedaquiline for tuberculosis

Affiliations

¹ Treatment Action Group, New York, NY 10016-7701, USA. Electronic address: erica.lessem@treatmentactiongroup.org.
² Boston University School of Medicine, Boston, MA, USA; National Tuberculosis Controllers Association, Smyrna, GA, USA.
³ Olive View-UCLA Medical Center Inpatient Tuberculosis Unit, Division of Infectious Diseases, Department of Medicine and David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
⁴ National Tuberculosis Controllers Association, Smyrna, GA, USA.

Comment

Erica M Lessem et al. Lancet. 2015.

. 2015 May 2;385(9979):1724.

doi: 10.1016/S0140-6736(15)60885-6.

¹ Treatment Action Group, New York, NY 10016-7701, USA. Electronic address: erica.lessem@treatmentactiongroup.org.
² Boston University School of Medicine, Boston, MA, USA; National Tuberculosis Controllers Association, Smyrna, GA, USA.
³ Olive View-UCLA Medical Center Inpatient Tuberculosis Unit, Division of Infectious Diseases, Department of Medicine and David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
⁴ National Tuberculosis Controllers Association, Smyrna, GA, USA.

No abstract available

Comment in

Informed use of bedaquiline for tuberculosis--Authors' reply.
Mingote LR, Namutamba D, Seaworth B, Lee C, Frick MW. Mingote LR, et al. Lancet. 2015 May 2;385(9979):1725. doi: 10.1016/S0140-6736(15)60887-X. Lancet. 2015. PMID: 25943935 No abstract available.

The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities.
Mingote LR, Namutamba D, Apina F, Barnabas N, Contreras C, Elnour T, Frick MW, Lee C, Seaworth B, Shelly D, Skipper N, dos Santos Filho ET. Mingote LR, et al. Lancet. 2015 Jan 31;385(9966):477-9. doi: 10.1016/S0140-6736(14)60523-7. Epub 2014 Jul 10. Lancet. 2015. PMID: 25018118 No abstract available.